Literature DB >> 978852

Inhibitory effect of (+)threo-3,4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops.

C Inagaki, H Fujiwara, C Tanaka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 978852     DOI: 10.1254/jjp.26.380

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


× No keyword cloud information.
  7 in total

1.  Reversal of the reserpine-induced ptosis by L-threo-3,4-dihydroxy-phenylserine (L-threo-DOPS), a (-)-norepinephrine precursor, and its potentiation by imipramine or nialamide.

Authors:  T Kato; M Katsuyama; N Karai; A Hirose; M Nakamura; J Katsube
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

2.  Role of catechol structure in the inhibitory effects of D-isomers of amino acids on the decarboxylation of L-5-hydroxytryptophan.

Authors:  T Shikimi; C Inagaki; S Takaori
Journal:  Experientia       Date:  1978-09-15

3.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

Review 4.  L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

Authors:  Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

5.  Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; S Sakoda; M Ueji; A Hayashi; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  DL-threo-DOPS as a precursor of noradrenaline.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

7.  Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; I Tsuge; S Sakoda; A Hayashi; Y Yamamura; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.